The massive EPS beat and $1B+ cash runway de-risk the stock significantly for the next two years, but revenue declined YoY and the company has no approved products. Watch for Phase 3 data readouts in mid-2028 and potential partnership or licensing deals for rezpegaldesleukin as key catalysts.
Price Chart
Executive Summary
Nektar Therapeutics reported Q2 2026 EPS of -$1.23, a 39.6% beat vs consensus of -$2.04, on revenue of $10.1M (slightly below $10.5M consensus). The company ended the quarter with $1.02B in cash, extending its runway into Q3 2028, and initiated Phase 3 trials for lead candidate rezpegaldesleukin in atopic dermatitis. The strong EPS beat and robust cash position are positive, but revenue declined YoY and the company remains pre-commercial with no near-term catalyst for profitability.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$1.23 beat consensus of -$2.04 by 39.6%
- Revenue of $10.1M vs consensus $10.5M (miss of ~3.8%)
- Cash and investments of $1,023.4M, up from $245.8M at Dec 31, 2025
- Cash runway extends into Q3 2028, past initial Phase 3 data readouts in mid-2028
- Initiated Phase 3 ZENITH AD program for rezpegaldesleukin in atopic dermatitis in July 2026
- Completed $373.8M public offering in April 2026
- Net loss of $40.6M narrowed from $41.6M in Q2 2025
- R&D expense increased to $39.1M from $29.9M YoY, driven by Phase 3 preparation
Financial Impact
EPS beat of $0.81 vs consensus; cash position strengthened by $777.6M since Dec 2025
Risk Factors
- Revenue declined 9.6% YoY to $10.1M
- No approved products; entirely dependent on clinical-stage pipeline
- Phase 3 trials carry inherent risk of failure
- Operating expenses increased 10.7% YoY, driven by R&D ramp
- Accumulated deficit grew to $3.85B
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302851330 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 9w ago | Press Release | $73.02 $68.50 | ▼ −6.19% | ▼ −4.20% | $35.78 (−51.00%) |
Aug 9, 2026 10w ago | Institutional Cluster | $74.86 $75.44 | ▲ +0.77% | ▲ +1.69% | $35.78 (−52.20%) |
Aug 7, 2026 10w ago | Court Ruling | $76.48 $74.19 | ▼ −2.99% | ▼ −2.60% | $35.78 (−53.22%) |
Jul 28, 2026 11w ago | Press Release | $70.68 $73.77 | ▲ +4.37% | ▼ −0.65% | $35.78 (−49.38%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
Jun 11, 2026 18w ago | Institutional Cluster | $59.21 $72.92 | ▲ +23.15% | ▲ +21.26% | $35.78 (−39.57%) |
May 21, 2026 21w ago | Insider Cluster | $66.61 $65.25 | ▲ +2.04% | ▲ +0.63% | $35.78 (+46.28%) |
May 8, 2026 23w ago | 8-K | $78.72 $56.23 | ▲ +28.57% | ▲ +28.27% | $35.78 (+54.55%) |
May 7, 2026 23w ago | 8-K | $81.89 $57.32 | ▼ −30.00% | ▼ −30.03% | $35.78 (−56.31%) |
Apr 24, 2026 25w ago | DEFA14A | $86.74 $65.56 | ▼ −24.42% | ▼ −29.37% | $35.78 (−58.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access